Breaks Categories: Stock Spotlights

ThursdayJan 05, 2017 10:45 am

NetworkNewsBreaks – How Caladrius Biosciences, Inc. (NASDAQ: CLBS) is Tackling Type 1 Diabetes Mellitus

Autoimmune diseases cost the U.S. more than $100 million annually. Immune tolerance happens, among other things, from the suppression of self-reactive T effector cells and auto-antigen presenting cells by T-regulatory (Treg) cells. A deficit of T-regulatory cells can lead to serious allergic and autoimmune diseases, such as Type 1 diabetes mellitus (T1DM). Caladrius Biosciences (NASDAQ: CLBS) uses T Regulatory Cell Technology to increase autologous T-regulatory cells and function, representing the potential for "true disease modification." The company is developing a therapy based on this technology (CLBS03) for the treatment of T1DM. After announcing positive results for a phase 1 study…

Continue Reading

WednesdayJan 04, 2017 12:25 pm

NetworkNewsBreaks – Finjan Holdings, Inc. (NASDAQ: FNJN) Shares Continue Rally on Licensing Agreement, Record Revenues of $18M

Shares of cybersecurity provider Finjan Holdings (NASDAQ: FNJN) are up 9%, continuing a rally on yesterday’s news that the company’s Finjan, Inc. subsidiary is closing a Confidential Patent License Agreement with F5 Networks, Inc. The company also reported record revenues stemming from initiatives to lower costs and maximize efficiencies. "The F5 license agreement is meaningful as it is the first under our enhanced licensing program initiated to streamline efforts, reduce costs and improve efficiencies. As a result of our enforcement efforts we closed a record year at Finjan with more than $18 million in revenue, an almost four-fold increase over…

Continue Reading

WednesdayJan 04, 2017 12:22 pm

NetworkNewsBreaks – Inventergy Global, Inc. (NASDAQ: INVT) Kicks-off Patent Licensing Campaign for GTX Corp (GTXO) Technology

IP licensing and innovation company Inventergy Global (NASDAQ: INVT) this morning said its subsidiary, Inventergy Innovations, LLC,  has launched a patent licensing campaign for GTX Corp (OTC: GTXO) for its wireless location-based services IP assets based on two-way GPS tracking. As a follow-up to a definitive agreement announced in June 2016, the licensing campaign will provide substantial discounts for early adoption, multi-year commitments or higher volumes of products to companies interested in the Comm. Protocol family. "In our Inventergy Innovations model we obtain exclusive rights to license or sell a partner's patents, technology or in some cases their entire company. We use…

Continue Reading

WednesdayJan 04, 2017 12:18 pm

NetworkNewsBreaks – Bellerophon Therapeutics, Inc. (NASDAQ: BLPH): FDA Approves Protocol Changes for Phase 3 INOpulse Program, Shares Tick Higher

Bellerophon Therapeutics (NASDAQ: BLPH) this morning said the U.S. FDA has approved proposed modifications to the company’s phase 3 program for INOpulse in Pulmonary Arterial Hypertension (PAH). The protocol changes have the potential to reduce the time to market and are expected to result in “substantial” costs savings. “We are gratified that the FDA has agreed with the proposed modifications to our PAH Phase 3 program, which have the potential to make INOpulse available to PAH patients approximately two years earlier than otherwise would have been possible under the original Phase 3 program,” Bellerophon president and CEO Fabian Tenenbaum stated…

Continue Reading

TuesdayJan 03, 2017 1:17 pm

NetworkNewsBreaks – Bridgeline Digital, Inc.’s (NASDAQ: BLIN) iAPPS Product Suite Helps Businesses Enhance Digital Assets

Today’s companies increasingly rely on the effectiveness of digital assets for a variety of business functions. Websites, mobile applications and online stores, for example, are now the most powerful marketing tools available. Focusing on digital values, Bridgeline Digital (NASDAQ: BLIN) offers interactive technology solutions designed to enhance a company's web properties. Its iAPPS product suite is a digital engagement platform that incorporates everything from web content management and eCommerce to digital marketing and web analytics. Recently, the iAPPS product suite was chosen by one of the world’s largest engine manufacturers to power its eCommerce website. It allows the company to…

Continue Reading

TuesdayJan 03, 2017 1:11 pm

NetworkNewsBreaks – Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Obtains Orphan Drug Designation for Fragile X Syndrome Treatment

Marinus Pharmaceuticals (NASDAQ: MRNS) this morning said that the FDA has granted Orphan Drug Designation to the company’s CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome, the most common genetic cause of autism, which is caused by a mutation in the FMR1 gene. This designation provides Marinus with a seven-year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act filing fees. “We are pleased to receive Orphan Drug Designation from the…

Continue Reading

TuesdayJan 03, 2017 1:07 pm

NetworkNewsBreaks – Kopin Corp. (NASDAQ: KOPN) Shares Spike on $23.9M Partnership Deal with Goertek, Inc.

Shares of Kopin (NASDAQ: KOPN) are up nearly 13% after the wearable technologies company announced its strategic relationship with China-based Goertek Inc., a global technology company that provides vertically-integrated total solutions and services to companies such as Samsung, Sony (NYSE: SNE),and Microsoft (NASDAQ: MSFT). Per the agreement, Kopin will sell 7,339,000 shares of its common stock to Goertek for $23.8 million ($3.25 per share). The two companies have also agreed to jointly develop and commercialize a range of technologies and wearable products. The stock sale is subject to standard closing conditions and is scheduled for completion by January 27, 2017.…

Continue Reading

TuesdayJan 03, 2017 1:03 pm

NetworkNewsBreaks – Mindful of “Tap and Go” Payment Trend, Net Element (NASDAQ: NETE) Fine-tunes Value-added Services

Unified Payments, a TOT Group company owned by Net Element, Inc. (NASDAQ: NETE), provides secure mobile payments with value added services, honing its focus on increasing demands for specific services within the $180 billion mobile payments industry. “With ‘tap and go’ payments becoming more and more popular, customers expect this service to be available to them. As a result, simply paying via mobile is no longer the key driver for adoption of this relatively new payment method. The focus for mobile payments “is shifting from changing the payments process into a ‘buying experience’,” according to Mobile Payments Today (http://nnw.fm/Y4ktf). With…

Continue Reading

TuesdayJan 03, 2017 1:00 pm

NetworkNewsBreaks – New Age Beverages Corp. (NBEV) Aims for Leading Spot in Niche of Global Beverage Industry

New Age Beverages (OTC: NBEV) is focused on becoming the world’s largest healthy functional beverage company. In November, New Age posted third quarter net sales of $13.4 million, up 10% from the year prior. The company's third quarter EBITDA of $446,205 represents a year-over-year increase of 120%. In its earnings statement, the company also noted its consolidation agreement with Marley Beverage Company, which doubled the sales footprint for both companies and increased the portfolio of brands. Though the two companies will continue to operate as separate financial entities, New Age noted that the revenues of the combined group totals $70 million.…

Continue Reading

TuesdayJan 03, 2017 11:01 am

NetworkNewsBreaks – VBI Vaccines, Inc. (NASDAQ: VBIV) Aims to Halt Global Spread of Hepatitis B

VBI Vaccines (NASDAQ: VBIV) develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology. The commercial-stage company recently received $23.6 million in financing to advance its growing pipeline, which includes its Sci-B-Vac™ hepatitis B vaccine. Globally, more than two billion people show serological evidence of hepatitis B virus (HBV), which results in approximately 780,000 HBV-related deaths each year. While second-generation HBV vaccines contain only one surface antigen, Sci-B-Vac™ contains three viral surface antigens. This composition may provide more opportunities for the immune system to respond with antibodies that can recognize one or more components of the hepatitis…

Continue Reading